Lilly Rebounds 13% as Street Firms Up Targets

Short interest is thin and does not represent an interesting angle here. At roughly 0.93% of the free float, there is simply not much of a short case being pressed. The short score of 29.9 — running near the bottom of ORTEX's scale — confirms this. The borrow rate has crept higher, up 71% week-on-week to 0.52%, but from such a low base that it represents no real friction. Borrow availability is completely loose, with over 9,900% of short interest available to lend. There is no squeeze dynamic, no meaningful positioning to unwind.

Options sentiment has eased in line with the rally. The put/call ratio is running at 1.03, notably below its 20-day mean of 1.11 and roughly one standard deviation softer than the prior defensive posture — which, at a reading of 1.39, was the highest of the past year. That elevated PCR was consistent with hedging ahead of an uncertain earnings print. As the stock delivered, protection demand faded. The current reading is closer to neutral than defensive.

Institutional holders remain broadly constructive. Vanguard and BlackRock both added to positions in their most recent filings, collectively adding around 1.98 million shares. FMR (Fidelity) and T. Rowe Price each added over 1.4 million shares — active managers expanding exposure, not trimming. Lilly Endowment remains the largest holder at 10.3% of shares, though it trimmed modestly. The insider picture is thin and dated — the most recent trades on file are from February, routine award-and-sell sequences for the CFO and two executive vice presidents, all at $1,040. Nothing at current prices.

Valuation has moved with the stock. The trailing P/E is now 25.7x, up 2.6 points on the week, while the price-to-book is at 14.9x — both expanding off the April lows. EV/EBITDA, at 20.9x, has actually eased slightly on a 30-day view as earnings estimates moved up faster than the multiple. EPS momentum ranks in the 83rd percentile on a 30-day basis and the 74th on 90 days, suggesting estimate revisions are still running in LLY's favour. Peer pharma names put in a more subdued week: MRK added 2.8% and JNJ was flat, while AZN fell 4.1% and BMY dropped 2.2% — LLY's outperformance was not a sector rotation effect but a company-specific re-rating on the back of its own results.

What to watch next: whether the post-earnings momentum in analyst estimate revisions sustains into the summer, and how the stock trades relative to that $1,207 consensus target as the August 5 report approaches.